Incresaed levels of CEA are found in patients with primary Colorectal carcinoma and other malignancies like Medullary thyroid carcinoma and Carcinoma of breast, GI tract, liver, lung, ovarian, pancreatic and prostate. Serial monitoring of CEA should begin prior to therapy to establish a baseline for evaluating possible recurrence.